Nitroglicerina Eg Stada (Glyceryl Trinitrate)

Glyceryl trinitrate, the active ingredient in Nitroglicerina Eg Stada, is an organic nitrate presented as a transdermal patch for transdermal use. It is employed to relieve acute angina pectoris, reduce the frequency of chronic stable angina attacks, and improve symptoms of heart failure in adult patients, and is indicated for use under medical supervision.

GNH USA supplies Nitroglicerina Eg Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU regulatory standards and providing reliable global distribution.

Nitroglicerina Eg Stada (glyceryl trinitrate) is an organic nitrate used in the management of coronary artery disease. - Acute angina pectoris: provides rapid relief of chest pain by reducing myocardial oxygen demand. - Chronic stable angina: decreases the frequency of angina attacks and improves exercise tolerance. - Heart failure: lowers preload and afterload, helping to alleviate symptoms and improve functional capacity.

Adverse reactions to Nitroglicerina Eg Stada are generally related to its vasodilatory action.

Common Side Effects: - Headache: throbbing pain often occurring shortly after application. - Dizziness: sensation of light‑headedness or imbalance. - Flushing: warm sensation and reddening of the skin. - Hypotension: drop in blood pressure, especially when standing. - Tachycardia: increased heart rate as a reflex response. - Skin irritation: redness or itching at the patch site.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Syncope: sudden loss of consciousness. - Myocardial infarction: rare occurrence of heart attack. - Allergic reaction: rash, swelling, or difficulty breathing. - Methemoglobinemia: rare blood disorder causing reduced oxygen delivery.

When prescribing Nitroglicerina Eg Stada, clinicians should consider several safety precautions. - Cardiovascular monitoring: assess blood pressure and heart rate before and during therapy. - Concomitant PDE‑5 inhibitors: avoid co‑administration due to risk of severe hypotension. - Surgery or anesthesia: discontinue the patch at least 24 hours before planned procedures. - Tolerance development: implement drug‑free intervals as advised to maintain efficacy. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Nitroglicerina Eg Stada may interact with other medicines, altering its effects or safety profile.

Major Interactions (Avoid): - PDE‑5 inhibitors (e.g., sildenafil, tadalafil): combined use can cause profound hypotension. - Other nitrates (e.g., isosorbide dinitrate): additive vasodilation may lead to severe blood‑pressure‑fall. - Antihypertensive agents (e.g., ACE inhibitors, ARBs): may enhance blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics and beta‑blockers: may increase risk of hypotension and dizziness. - Alcohol and tobacco: alcohol can potentiate hypotensive effect, while tobacco induces metabolism reducing efficacy.